Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00676533 · ClinicalTrials.gov registry record · Phase 4
Cipro® XR in Therapeutic Response and Activity (eXtRa) - Assessing Symptom Relief in Urinary Tract Infections
A Phase 4 study, sponsored by Bayer.
- Completed
- Registry status
- Phase 4
- Development phase
- 276
- Enrollment target
NCT00676533 is a Phase 4 study that has completed, run by Bayer. The registered enrollment target is 276 participants.
The verdict
NCT00676533, a Phase 4 study, has completed, sponsored by Bayer.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 276 participants
- Enrollment target
Study Summary
The primary objective of this clinical trial was to determine the time to improvement of the signs and symptoms (eg, dysuria, frequency, urgency, gross hematuria, suprapubic pain, hesitancy, low back pain) of acute, uncomplicated, symptomatic, lower UTIs in women treated with Cipro XR 500 mg once daily for 3 days.
Interventions
- DRUG Cipro XR (Ciprofloxacin, BAYQ3939)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 276 participants |
| Start Date | 2003-06 |
| Est. Completion | 2004-01 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00676533
The ClinicalTrials.gov registry entry for NCT00676533 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 276 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bayer, which has 591 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Cipro XR (Ciprofloxacin, BAYQ3939) is the first listed.
NCT00676533 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00676533 about?
NCT00676533 is a clinical study titled "Cipro® XR in Therapeutic Response and Activity (eXtRa) - Assessing Symptom Relief in Urinary Tract Infections". The primary objective of this clinical trial was to determine the time to improvement of the signs and symptoms (eg, dysuria, frequency, urgency, gross hematuria, suprapubic pain, hesitancy, low back pain) of acute, uncomplicated, symptomatic, lower UTIs in women treated with Cipro XR 500 mg once da...
What is the current status of trial NCT00676533?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 276 participants. The study started on 2003-06. Estimated completion is 2004-01.
What interventions are being tested in trial NCT00676533?
The interventions under investigation include: Cipro XR (Ciprofloxacin, BAYQ3939) (DRUG).
Who is sponsoring clinical trial NCT00676533?
This trial is sponsored by Bayer, which has 591 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.